dacarbazine has been researched along with Hyperprolactinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilbao, I; Egaña, N; García, C; Olaizola, I | 1 |
| Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D | 1 |
2 other study(ies) available for dacarbazine and Hyperprolactinemia
| Article | Year |
|---|---|
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide | 2017 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dopamine Agonists; Hormone Replacement Therapy; Humans; Hyperprolactinemia; Hypophysectomy; Hypopituitarism; Male; Multiple Endocrine Neoplasia Type 1; Mutation, Missense; Neoplasm Recurrence, Local; Ophthalmoplegia; Pancreatic Neoplasms; Parathyroid Neoplasms; Pituitary Apoplexy; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins; Radiotherapy, Adjuvant; Remission Induction; Spinal Neoplasms; Temozolomide | 2012 |